Q-omics provides the consensus-scored ZNF726 profile across patient tissues and cancer cell-line models. ZNF726 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF726 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, ZNF726 RNA expression shows 17,611 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where ZNF726 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF726 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF726 survival associations across molecular data types. ZNF726 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF726 RNA expression–survival associations across cancer types. High ZNF726 expression shows unfavorable associations in KIRC, UVM and BRCA, but favorable associations in BLCA, LUAD and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF726 RNA expression.
This table summarizes ZNF726 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF726. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF726 shows lower tumor expression in KIRC, COAD and KIRP and higher tumor expression in UCEC, LUAD and BLCA. The KIRC box plot shows higher ZNF726 RNA expression in normal versus tumor tissue (log2 FC = −0.823, t-test p < 0.001).
This table shows molecular features associated with ZNF726 in patient tissues and cancer cell lines. In patient samples, ZNF726 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF726 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
